Table 4 Other complications following COVID-19 vaccines in Iran involvement
Case no | Type of disorder | Age | Gender | Comorbidity | COVID-19 test/history | Vaccine type | Time of incidence | Ref |
|---|---|---|---|---|---|---|---|---|
Ocular involvement | ||||||||
1 | Paracentral acute middle maculopathy | 38 | Male | – | Negative | BBIBP–CorV | 2 weeks after vaccination | [54] |
2 | Herpetic endotheliitis and stromal keratitis | 30 | Female | Hypothyroidism | Not stated | BBIBP–CorV | 2 weeks after vaccination | [55] |
3 | Intracranial hypertension and papilledema | 32 | Male | – | Not stated | Sputnik V | 3 days after the 1st dose | [56] |
4 | Acute macular neuroretinopathy | 18 | Female | – | Negative | BBIBP–CorV | 5 days after the 1st dose | [57] |
Liver involvement | ||||||||
5 | Fulminant hepatitis | 35 | Male | Controlled psychological problems | Not stated | ChAdOx1-S | 8 days after the 1st dose | [53] |
6 | Acute liver failure | 34 | Male | – | Not stated | ChAdOx1-S | 2 days after the 1st dose | [52] |
Thyroid disorder | ||||||||
7 | Subacute thyroiditis | 34 | Female | – | Negative | COVAXIN | 11 days after the 1st dose | [58] |
Graft rejection | ||||||||
8 | Corneal Graft Rejection | 36 | Female | Penetrating keratoplasty (PKP) secondary to herpes simplex keratitis (HSK) | Not stated | BBIBP–CorV | 7 days after the 1st dose | [59] |
9 | 54 | Female | Not stated | BBIBP–CorV | ||||